HSGX News

Histogenics, which is developing a tissue implant to repair knee cartilage using regenerative medicine, raised $65 million by offering 5.9 million shares at $11, well below the $13 to $15 range. Histogenics will list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham & Co. and Canaccord Genuity acted as joint bookrunners on the deal....read more

Histogenics, a biotech developing a therapy for repairing knee cartilage using its tissue repair platform, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Histogenics would command a fully diluted market value of $158 million. The...read more

Histogenics, a biotech developing an implantable tissue repair platform for cartilage damage to the knee, filed on Tuesday with the SEC to raise up to $65 million in an initial public offering. The company's lead candidate, NeoCart, uses a patient's own cartilage cells and creates a scaffold to engineer tissue growth, and then implants NeoCart at the injured knee. Histogenics...read more